Titles and abstracts were initially screened for relevance, followed by full-text review of potentially eligible articles
10.1113/EP090802 8 BadawyA
(8.1) CLINICAL PHARMACOLOGY : Mechanism of Action : Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones
The rapid release of this product is generally applied to those cases where support is needed in the upper gastrointestinal region as well as when more acute needs arise with regard to joint support
Human Growth Hormone (HGH) Although Human Growth Hormone (HGH) can be used alone, adding GHRP-6 or GHRP-2 provides a way to amplify natural GH pulsatility , even during exogenous HGH cycles: Helps maintain pituitary sensitivity Prevents desensitization from flat HGH levels Supports greater IGF-1 production and anabolic signaling GHRPs combined with exogenous GH therapy can enhance pulsatile GH release and improve treatment outcomes. Chapman , Journal of Clinical Endocrinology & Metabolism MK-677 (Ibutamoren) MK-677 (Ibutamoren) is an oral GH secretagogue that stimulates GH release via the same GHS-R1a receptorbut with a much longer half-life (24h)
BMJ 339, b2535, 10.1136/bmj.b2535 (2009)
